Avalanche rides gene therapy to $55 million VC round – Silicon Valley Business Journal

Avalanche rides gene therapy to $55 million VC round
Silicon Valley Business Journal
That protein blocks the signal of another protein, VEGF, that is key to the growth of new blood vessels that inhibit sight in patients with wet age-related macular degeneration. Today, wet AMD patients must receive five to seven injections a year with

and more

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment